Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C61590
http://purl.obolibrary.org/obo/NCIT_C61590
|
|---|---|
| Preferred Name | Nitrogen Mustard Prodrug PR-104 |
| Definitions |
A non-toxic, small-molecule, hypoxia-activated, 3,5-dinitrobenzamide nitrogen mustard pre-prodrug with potential antitumor activity. Upon intravenous administration, PR-104 is converted by systemic phosphatases to the alcohol intermediate PR-104A, which is reduced to form the active DNA-crosslinking mustard species hydroxylamine PR-104H intracellularly under hypoxic conditions. PR-104H specifically crosslinks hypoxic tumor cell DNA, resulting in the inhibition of DNA repair and synthesis, cell-cycle arrest, and apoptosis in susceptible hypoxic tumor cell populations while sparing normoxic tissues.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | A non-toxic, small-molecule, hypoxia-activated, 3,5-dinitrobenzamide nitrogen mustard pre-prodrug with potential antitumor activity. Upon intravenous administration, PR-104 is converted by systemic phosphatases to the alcohol intermediate PR-104A, which is reduced to form the active DNA-crosslinking mustard species hydroxylamine PR-104H intracellularly under hypoxic conditions. PR-104H specifically crosslinks hypoxic tumor cell DNA, resulting in the inhibition of DNA repair and synthesis, cell-cycle arrest, and apoptosis in susceptible hypoxic tumor cell populations while sparing normoxic tissues. |
|---|---|
| prefLabel | Nitrogen Mustard Prodrug PR-104
|
| label | Nitrogen Mustard Prodrug PR-104
|
| PDQ_Closed_Trial_Search_ID | 492222
|
| code | C61590
|
| Has_Target | |
| prefixIRI | NCIT:C61590
|
| in_subset |
See more
See less
|
| Display_Name | PR-104
|
| Preferred_Name | Nitrogen Mustard Prodrug PR-104
|
| FDA_UNII_Code | V16D2ZT7DT
|
| Contributing_Source |
CTRP
FDA
|
| Maps_To | Nitrogen Mustard Prodrug PR-104
|
| CAS_Registry | 851627-62-8
|
| NCI_Drug_Dictionary_ID | 492222
|
| Legacy Concept Name | PR-104
|
| type | |
| ALT_DEFINITION | A substance being studied in the treatment of cancer. PR-104 becomes active when cancer cells don't receive enough oxygen. It may kill cancer cells by damaging their DNA.
|
| Is_Value_For_GDC_Property | |
| subClassOf | |
| PDQ_Open_Trial_Search_ID | 492222
|
| Semantic_Type | Pharmacologic Substance
|
| UMLS_CUI | C1831907
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |